Organization, Basis of Presentation and Liquidity - Additional Information (Details) $ in Thousands		1 Months Ended		12 Months Ended
	Dec. 17, 2021 USD ($)	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2024 USD ($) Patients ClinicalTrials	Dec. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents and marketable securities				$ 47,800
Marketable Securities				2,000
Restricted cash				$ 100	$ 100
Number of clinical trials | ClinicalTrials				2
Number of patients in phase 1 | Patients				5
Number of patients in phase 1/2a | Patients				25
Clinical development cost				$ 14,300
Corporate Credit Card Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted cash				100
Parent Company [Member] | Sales Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount reserved for future issuance				$ 39,970
Roche Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment	$ 50,000	$ 50,000	$ 50,000
Maximum milestone payments to be received upon performance conditions		$ 620,000	$ 620,000